| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
2
|
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2002
|
3.30
|
|
3
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
2.81
|
|
4
|
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
|
Cancer
|
2006
|
2.77
|
|
5
|
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
|
Lancet Oncol
|
2012
|
2.25
|
|
6
|
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
|
Cancer
|
2003
|
2.21
|
|
7
|
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
|
Br J Haematol
|
2010
|
1.85
|
|
8
|
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
|
J Clin Oncol
|
2006
|
1.60
|
|
9
|
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
|
Blood
|
2004
|
1.49
|
|
10
|
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
|
Leuk Lymphoma
|
2011
|
1.46
|
|
11
|
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
|
Cancer J
|
2002
|
1.45
|
|
12
|
International prognostic index-based outcomes for diffuse large B-cell lymphomas.
|
Cancer
|
2002
|
1.36
|
|
13
|
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
|
Anticancer Res
|
2011
|
1.14
|
|
14
|
How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
|
Lancet Oncol
|
2010
|
1.11
|
|
15
|
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
|
Cancer
|
2008
|
1.02
|
|
16
|
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
|
Cancer
|
2006
|
1.01
|
|
17
|
Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections.
|
Am J Clin Pathol
|
2002
|
0.98
|
|
18
|
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.
|
J Clin Oncol
|
2002
|
0.96
|
|
19
|
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.
|
Blood
|
2002
|
0.93
|
|
20
|
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2003
|
0.93
|
|
21
|
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
|
Cancer
|
2002
|
0.92
|
|
22
|
Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma.
|
Am J Clin Oncol
|
2007
|
0.92
|
|
23
|
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.
|
Clin Cancer Res
|
2003
|
0.91
|
|
24
|
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
|
Blood
|
2002
|
0.89
|
|
25
|
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
|
Eur J Haematol
|
2006
|
0.87
|
|
26
|
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.
|
Clin Cancer Res
|
2003
|
0.87
|
|
27
|
Recent advances in the management of mantle cell lymphoma.
|
Curr Opin Oncol
|
2013
|
0.86
|
|
28
|
Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells.
|
Int J Hematol
|
2004
|
0.86
|
|
29
|
Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.
|
Am J Pathol
|
2002
|
0.84
|
|
30
|
Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.
|
Cancer Med
|
2013
|
0.84
|
|
31
|
Epigenetic therapy of lymphoma using histone deacetylase inhibitors.
|
Clin Transl Oncol
|
2010
|
0.84
|
|
32
|
Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2002
|
0.83
|
|
33
|
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
|
Am J Clin Oncol
|
2004
|
0.83
|
|
34
|
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
|
Br J Haematol
|
2013
|
0.82
|
|
35
|
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.82
|
|
36
|
The role of mitoxantrone in the treatment of indolent lymphomas.
|
Oncologist
|
2005
|
0.82
|
|
37
|
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
|
Cancer
|
2003
|
0.81
|
|
38
|
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.
|
Leuk Lymphoma
|
2004
|
0.81
|
|
39
|
Thalidomide for patients with recurrent lymphoma.
|
Cancer
|
2004
|
0.81
|
|
40
|
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
|
Cancer
|
2002
|
0.80
|
|
41
|
Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.
|
Cancer
|
2002
|
0.80
|
|
42
|
Stage III follicular lymphoma: long-term follow-up and patterns of failure.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.80
|
|
43
|
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options.
|
Hematology Am Soc Hematol Educ Program
|
2000
|
0.80
|
|
44
|
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
|
Cancer
|
2005
|
0.79
|
|
45
|
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations.
|
Lab Invest
|
2003
|
0.79
|
|
46
|
Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice.
|
Cancer
|
2004
|
0.79
|
|
47
|
Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma.
|
Leuk Lymphoma
|
2002
|
0.79
|
|
48
|
BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.
|
Clin Cancer Res
|
2002
|
0.78
|
|
49
|
Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
|
J Clin Oncol
|
2011
|
0.77
|
|
50
|
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.77
|
|
51
|
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
|
Semin Oncol
|
2002
|
0.77
|
|
52
|
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2006
|
0.77
|
|
53
|
Establishment and characterization of a new mantle cell lymphoma cell line M-1.
|
Leuk Lymphoma
|
2004
|
0.77
|
|
54
|
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
|
Br J Haematol
|
2014
|
0.76
|
|
55
|
Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico.
|
P R Health Sci J
|
2012
|
0.76
|
|
56
|
Therapeutic concepts in mantle cell lymphoma.
|
Eur J Haematol
|
2010
|
0.76
|
|
57
|
Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.
|
P R Health Sci J
|
2010
|
0.76
|
|
58
|
Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.76
|
|
59
|
Reply to I.E. Haines.
|
J Clin Oncol
|
2013
|
0.75
|
|
60
|
A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management.
|
Bol Asoc Med P R
|
2009
|
0.75
|
|
61
|
Diffuse large-cell lymphoma. Part II: management.
|
P R Health Sci J
|
2009
|
0.75
|
|
62
|
Severe anemia of rapid onset in an inmunocompromised host.
|
Bol Asoc Med P R
|
2009
|
0.75
|
|
63
|
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.75
|
|
64
|
Clinical and pathological features of colorectal cancer in patients at a community hospital in Puerto Rico.
|
P R Health Sci J
|
2014
|
0.75
|
|
65
|
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
|
Semin Oncol
|
2002
|
0.75
|
|
66
|
Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma.
|
Cancer
|
2002
|
0.75
|
|
67
|
Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma.
|
Cancer J
|
2003
|
0.75
|
|
68
|
Metastatic Ovarian Tumor Masquerading as Atypical Pneumonia.
|
Bol Asoc Med P R
|
2016
|
0.75
|
|
69
|
Diffuse large-cell lymphoma. Part I: clinical features, histology and prognosis.
|
P R Health Sci J
|
2009
|
0.75
|
|
70
|
POEMS Syndrome: A Rare Disease With A Challenging Diagnosis.
|
Bol Asoc Med P R
|
2016
|
0.75
|
|
71
|
Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21).
|
Cancer J
|
2004
|
0.75
|